Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Schering CEO defends Vytorin decisions
Talk about the hot seat. At a Morgan Stanely pharma conference yesterday, Schering-Plough CEO Fred Hassan (photo) was quizzed and re-quizzed by investors about the Vytorin-Zetia controversy. (In case you missed it, Schering and its partner Merck drew fire last month for allegedly holding back data on the cholesterol fighters, some from studies that indicate Zetia might cause liver problems, plus an entire trial pitting Zetia-plus-Zocor against Zocor alone.)
Hassan pooh-poohed the buzzing about the latter trial, saying that the 720 patients involved had very high cholesterol because of genetics, so that data shouldn't affect the use of Vytorin (which combines Zetia and Zocor) in regular patients. But investors at the meeting weren't satisfied. Pressing Hassan on the science of statins, they asked whether Vytorin--which is very good at lowering cholesterol--also carries all the benefits of other statins such as Lipitor. Hassan had no direct answer.
As for the liver questions, Schering's R&D chief Thomas Koestler acknowledged that some Zetia patients had abnormal results on liver-function tests, but they generally showed no symptoms. Serious problems, he said, "are extremely rare."
- read theĀ article from the Wall Street Journal Health Blog
Related Articles:
Merck, Schering backpedal on Vytorin. Report
A new 'religion' at Schering-Plough. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


